Opdivo+Yervoy's negotiations failed to reach an agreement

Only extended the period

The NHIS, up to 60 days of negotiations on drug prices, failed to reach an agreement and only extended the period

Approximately 4 years from August 2017 to get reimbursed

Improvement of overall survival period and response rate

Drugs for the combination of the immuno-cancer drugs Opidivo (Nivolumab) and Yervoy (Ipilimumab) in primary treatment for kidney cancer were not negotiated within days.

 

In the end, it is expected to take longer to apply the benefit.

 

According to related industries on the 1st, Ono Pharmaceutical and BMS have extended drug price negotiations with the NHIS for Opdivo and Yervoy kidney cancer primary treatment benefits.

 

Earlier, Opdivo and Yervoy combination therapy was recognized for their benefit adequacy and began drug negotiations with the NHIS for "median or high-risk progressive neocyte cancer treatment" at the HIRA.

 

Pharmaceutical price negotiations run for up to 60 days, and the recent period has expired.

 

The NHIS and pharmaceutical companies never reached an agreement.

 

However, they decided to extend it because they believed that additional negotiations were needed.

 

PD-1 inhibitor immuno-cancer drugs Opdivo and CTLA-4 inhibitor immuno-cancer drugs Yervoy demonstrated excellent effectiveness in primary treatment of kidney cancer.

 

In June 2020, and it passed the HIRA's Cancer Drugs Benefit Appraisal Committee.

 

Later, it took about nine more months for the HIRA's Pharmaceutical Benefits Advisory Committee to recognize the benefit adequacy.

 

In clinical trials of CheckMate-214 compared to the standard treatment of Sutene (Sunitinib Malate) in intermediate and high risk groups, Opdivo and Yervoy combined therapy showed a significant effect compared to the median (mOS) of 48.1 months, compared to 26.6 months.

 

The objective response rate was also significantly higher at 41.9% to 26.8% and the rate of patients maintaining it was higher (65.2% to 49.6%).

 

In particular, 10.4% of patients treated with combination therapy reached full response and received attention.

 

Professor Park Soo-hyung of Kaist GMSE said, "In immune mechanism, CTLA-4 activates priming, which is the first antigen-specific immune response, to induce T-cell reactions, and anti-PD-1 prevents degradation of T-cells, which can create synergies." If Opdivo and Yervoy therapy are listed, the use of immunocancer drugs in kidney cancer is expected to become more active.

 

This is also the first case in which immuno-cancer drug combination therapy is applied in chemotherapy.

 

Both companies are also seeking to expand insurance coverage for Opdivo and Yervoy combined therapy in primary care for non-small cell lung cancer.